ABVC BioPharma to break ground in China, advances 20% stake in Zhonghui real estate

18 Aug 2023
endpts.com
Acquisition
California-headquartered ABVC BioPharma is to expand its geographic reach through an acquisition agreement with Zhonghui United, with the biotech moving ahead with a 20% ownership stake in Zhonghui’s real estate in Chengdu, China.
The deal is worth approximately $7.4 million, which is in the ballpark of 370,000 shares of ABVC stock at $20 per share, as per ABVC’s Thursday press release.
According to an SEC filing, the land and property is in Leshan, Sichuan, China. The eventual facility is envisioned as ABVC’s “base for the China market and global development.”
ABVC BioPharma to break ground in China, advances 20% stake in Zhonghui real estate
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.